Patents by Inventor Silke Mark

Silke Mark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical formulation for use in spinal fusion
    Patent number: 10589001
    Abstract: A pharmaceutical formulation for use in a spinal fusion method, comprising a composition for forming a matrix, a kit comprising the composition, a pharmaceutical product obtainable from the pharmaceutical formulation, and an interbody spinal fusion cage containing the pharmaceutical formulation or the pharmaceutical product are described herein. The composition comprises at least a first matrix material precursor component and a second matrix material precursor component that are able to crosslink to form the matrix under appropriate conditions, a bioactive factor that is biologically active for stimulating bone formation between two vertebrae and for effecting or supporting spinal fusion. The bioactive factor is PTH, optionally a PTH fusion peptide. The bioactive factor is releasably incorporated in the matrix upon crosslinking of the matrix material precursor components.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: March 17, 2020
    Assignee: Kuros Biosurgery AG
    Inventors: Jason Schense, Silke Mark, Monica Alvisi, Maria Angeles Martinez Vargas
  • PHARMACEUTICAL FORMULATION FOR USE IN SPINAL FUSION
    Publication number: 20120234718
    Abstract: A pharmaceutical formulation for use in a spinal fusion method, comprising a composition for forming a matrix, a kit comprising the composition, a pharmaceutical product obtainable from the pharmaceutical formulation, and an interbody spinal fusion cage containing the pharmaceutical formulation or the pharmaceutical product are described herein. The composition comprises at least a first matrix material precursor component and a second matrix material precursor component that are able to crosslink to form the matrix under appropriate conditions, a bioactive factor that is biologically active for stimulating bone formation between two vertebrae and for effecting or supporting spinal fusion. The bioactive factor is PTH, optionally a PTH fusion peptide. The bioactive factor is releasably incorporated in the matrix upon crosslinking of the matrix material precursor components.
    Type: Application
    Filed: September 7, 2011
    Publication date: September 20, 2012
    Inventors: Jason Schense, Silke Mark, Monica Alvisi, Maria Angeles Martinez Vargas
  • Medicament containing a tissue inhibitor of metalloproteinases-2 (TIMP-2) as an osteoanabolically active substance
    Patent number: 7232796
    Abstract: The invention relates to tissue inhibitor of metalloproteinase-2 (TIMP-2) as an osteoanabolically active peptide for use as a medicament for treating bone defects, bone diseases and for improving bone regeneration.
    Type: Grant
    Filed: April 4, 2001
    Date of Patent: June 19, 2007
    Assignee: IPF PharmaCeuticals GmbH
    Inventors: Franz-Josef Kramer, Silke Mark, Ludger Ständker, Wolf-Georg Forssmann
  • Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteoanabolically active substance
    Publication number: 20030195143
    Abstract: The invention relates to TIMP-2) as an osteoanabolically active peptide for use as a medicament for treating bone defects, bone diseases and for improving bone regeneration.
    Type: Application
    Filed: December 11, 2002
    Publication date: October 16, 2003
    Inventors: Franz-Josef Kramer, Silke Mark, Ludger Standker, Wolf-Georg Forssmann